Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan-Feb;8(1):44-55.
doi: 10.6004/jadpro.2017.8.1.4. Epub 2017 Jan 1.

Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications

Erin Armideo  1 , Colleen Callahan  1 , Lara Madonia  1
Affiliations
Review

Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications

Erin Armideo et al. J Adv Pract Oncol. 2017 Jan-Feb.

Abstract

Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials. Immunotherapy has become the standard of care for patients with high-risk disease, and many institutions across the country are providing this therapy. The care of these patients is complex and often associated with many side effects. The purpose of this article is to review the most common side effects seen in clinical practice and examine their management. Furthermore, this article will discuss the need for a consistent and educated multidisciplinary front-line team to care for these patients, with advanced practitioners playing a lead role to provide the care and attention needed for this patient population.

PubMed Disclaimer

Figures

Figure
Figure
Overall Schema for Treatment With Dinutuximab. cis-RA = cis-retinoic acid; GM-CSF = granulocyte macrophage colony-stimulating factor; IL-2 = interleukin-2.
Appendix A.
Appendix A.
Appendix A. Dinutuximab Algorithm: Receiving Clinician Accepting Checklist
Appendix B.
Appendix B.
Appendix B. Dinutuximab Algorithm: Mild Allergic Reaction
Appendix C.
Appendix C.
Appendix C. Dinutuximab Algorithm: Severe Allergic Reaction
Appendix D.
Appendix D.
Appendix D. Dinutuximab Algorithm: Hypotension
Appendix E
Appendix E
Appendix E. Dinutuximab Algorithm: Discharge Checklist
See this image and copyright information in PMC

References

    1. Brodeur G M, Seeger R C, Schwab M, Varmus H E, Bishop J M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (New York, N.Y.) 1984;224:1121–1124. - PubMed
    1. Cohn Susan L, Pearson Andrew D J, London Wendy B, Monclair Tom, Ambros Peter F, Brodeur Garrett M, Faldum Andreas, Hero Barbara, Iehara Tomoko, Machin David, Mosseri Veronique, Simon Thorsten, Garaventa Alberto, Castel Victoria, Matthay Katherine K. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27:289–297. - PMC - PubMed
    1. Greengard E, Hill-Kayser C, Bagatell R. Treatment of high-risk neuroblastoma in children: Recent clinic trial results. Clinical Investigation. 2013;3(11):1071–1081.
    1. Irwin Meredith S, Park Julie R. Neuroblastoma: paradigm for precision medicine. Pediatric clinics of North America. 2015;62:225–256. - PubMed
    1. Kreissman Susan G, Seeger Robert C, Matthay Katherine K, London Wendy B, Sposto Richard, Grupp Stephan A, Haas-Kogan Daphne A, Laquaglia Michael P, Yu Alice L, Diller Lisa, Buxton Allen, Park Julie R, Cohn Susan L, Maris John M, Reynolds C Patrick, Villablanca Judith G. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet. Oncology. 2013;14:999–1008. - PMC - PubMed

LinkOut - more resources